Bristol-Myers Squibb (BMY) vs Novartis (NVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bristol-Myers Squibb (BMY) has outperformed Novartis (NVS) over the past year, gaining 27.1% versus a gain of 18.2%. Over five years, NVS leads with a +86.5% price change compared with +4.0% for BMY. Novartis is the larger company by market cap ($284.18 billion vs $120.19 billion), about 2.4 times the size.
On valuation, Bristol-Myers Squibb trades at a lower forward P/E (8.8x vs 15.1x for Novartis). Bristol-Myers Squibb offers the higher dividend yield (4.29% vs 3.10%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMY | NVS |
|---|---|---|
| Share price | $58.80 | $150.47 |
| Market cap | $120.19B | $284.18B |
| 1-day change | +0.79% | -0.50% |
| YTD return | +9.01% | +9.14% |
| 1-year return | +27.14% | +18.19% |
| 5-year return | +4.02% | +86.46% |
| P/E ratio (TTM) | 13.04 | 28.72 |
| Forward P/E | 8.78 | 15.15 |
| EPS (TTM) | $4.51 | $5.24 |
| Dividend yield | 4.29% | 3.10% |
| Annual dividend | $2.52 | $4.67 |
| Revenue (latest FY) | $48.19B | — |
| Revenue growth (YoY) | -0.22% | — |
| Net income (latest FY) | $7.05B | $13.98B |
| Gross margin | 71.08% | — |
| Net margin | 14.64% | — |
| 52-week high | $68.64 | $170.46 |
| 52-week low | $47.58 | $126.50 |
| Distance from 52-week high | -14.34% | -11.73% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +10.97% | +4.41% |
| Average volume | 11.15M | 2.18M |
| Shares outstanding | 2.04B | 1.89B |
| Employees | 32,500 | 75,267 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Novartis is about 2.4 times larger than Bristol-Myers Squibb by market value ($284.18B vs $120.19B).
- Novartis trades at a higher earnings multiple (28.7x vs 13.0x trailing P/E).
- Bristol-Myers Squibb offers a meaningfully higher dividend yield (4.29% vs 3.10%).
About Bristol-Myers Squibb
BMY stock →Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 32,500 employees
About Novartis
NVS stock →Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75,267 employees
BMY vs NVS FAQ
Which is bigger, Bristol-Myers Squibb or Novartis?
Novartis (NVS) is larger, with a market capitalization of $284.18B compared with $120.19B for Bristol-Myers Squibb (BMY).
Which stock has performed better over the past year, BMY or NVS?
BMY returned +27.14% over the past 12 months, compared with +18.19% for NVS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BMY or NVS?
BMY has the lower trailing P/E at 13.0, versus 28.7 for NVS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Bristol-Myers Squibb or Novartis?
Bristol-Myers Squibb has the higher yield at 4.29%, compared with 3.10% for Novartis.
Are Bristol-Myers Squibb and Novartis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.